News and Announcements
Leading health-tech company, Shivom raise $35 million during ICO
- Published December 18, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- The health-tech company raised $35 million during ICO
- MOU agreement signed with the State of Andhra Pradesh Government
- SignularityNet Partnership
- Genetic Technologies Limited Partnership
- eMQT Partnership
- Diabetes Programme
- Alpha Platform Release
Shivom is a leading health-tech company Shivom is a leading health-tech company focused on developing the world’s largest DNA data and healthcare services platform powered by blockchain technology.
This past year has been eventful for the company adding multiple partnerships from SingularityNet to Genetic Technologies Limited.
The company also launched their Diabetes study in September with the goal of finding unique genetic markers specific to Indian subpopulations that may help explain why the country has one of the highest rising prevalence’s of Type 2 Diabetes in the world.
Shivom opened up the end of the last quarter with the launch of their alpha release.
The release allows individuals to upload and store their DNA data securely, more importantly,
they ‘own’ their data so that they can choose to monetise it in the future, getting their fair
share of the $70bn pharmaceutical companies are paying annually for research and
development trials.
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
